|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/25/22 Rubius Therapeutics, Inc. 10-K 12/31/21 74:10M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.63M
2: EX-10.5 Material Contract HTML 28K
3: EX-21.1 Subsidiaries List HTML 22K
4: EX-23.1 Consent of Expert or Counsel HTML 21K
5: EX-31.1 Certification -- §302 - SOA'02 HTML 28K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 28K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 23K
8: EX-32.2 Certification -- §906 - SOA'02 HTML 23K
14: R1 Document and Entity Information HTML 91K
15: R2 Condensed Consolidated Balance Sheets HTML 116K
16: R3 Condensed Consolidated Balance Sheets HTML 39K
(Parenthetical)
17: R4 Condensed Consolidated Statements of Operations HTML 65K
and Comprehensive Loss
18: R5 Condensed Consolidated Statements of Operations HTML 24K
and Comprehensive Loss (Parenthetical)
19: R6 Condensed Consolidated Statements Stockholders HTML 85K
Equity
20: R7 Condensed Consolidated Statements Stockholders HTML 23K
Equity (Parenthetical)
21: R8 Condensed Consolidated Statements of Cash Flows HTML 118K
22: R9 Nature of the Business and Basis of Presentation HTML 31K
23: R10 Summary of Significant Accounting Policies HTML 64K
24: R11 Investments and Fair Value of Financial Assets and HTML 95K
Liabilities
25: R12 Property, Plant and Equipment, Net HTML 47K
26: R13 Accrued Expenses and Other Current Liabilities HTML 35K
27: R14 Debt HTML 53K
28: R15 Equity HTML 30K
29: R16 Stock-Based Compensation HTML 105K
30: R17 Income Taxes HTML 93K
31: R18 Commitments and Contingencies HTML 29K
32: R19 Leases HTML 84K
33: R20 Net Loss per Share HTML 54K
34: R21 Summary of Significant Accounting Policies HTML 109K
(Policies)
35: R22 Summary of Significant Accounting Policies HTML 29K
(Tables)
36: R23 Investments and Fair Value of Financial Assets and HTML 96K
Liabilities (Tables)
37: R24 Property, Plant and Equipment, Net (Tables) HTML 45K
38: R25 Accrued Expenses and Other Current Liabilities HTML 35K
(Tables)
39: R26 Debt (Tables) HTML 47K
40: R27 Stock-Based Compensation (Tables) HTML 103K
41: R28 Income Taxes (Tables) HTML 90K
42: R29 Leases (Tables) HTML 81K
43: R30 Net Loss per Share (Tables) HTML 55K
44: R31 Nature of the Business and Basis of Presentation HTML 58K
(Details)
45: R32 Summary of Significant Accounting Policies HTML 37K
(Details)
46: R33 Summary of Significant Accounting Policies - HTML 35K
Estimated useful life (Details)
47: R34 Investments and Fair Value of Financial Assets and HTML 61K
Liabilities (Details)
48: R35 Property, Plant and Equipment, Net (Details) HTML 56K
49: R36 Accrued Expenses and Other Current Liabilities HTML 34K
(Details)
50: R37 Debt (Details) HTML 80K
51: R38 Debt - Current and Non current (Details) HTML 34K
52: R39 Equity (Details) HTML 52K
53: R40 Stock-Based Compensation (Details) HTML 38K
54: R41 Stock-Based Compensation - Granted to HTML 30K
non-employees, prior to the adoption of ASU
2018-07 (Details)
55: R42 Stock-Based Compensation - Option activity HTML 78K
(Details)
56: R43 Stock-Based Compensation - Performance based stock HTML 51K
options (Details)
57: R44 Stock-Based Compensation - Restricted Common Stock HTML 57K
(Details)
58: R45 Stock-Based Compensation - Compensation expense HTML 36K
(Details)
59: R46 Income Taxes (Details) HTML 46K
60: R47 Income Taxes - U S federal statutory income tax HTML 42K
rate (Details)
61: R48 Income Taxes - Net deferred tax assets (Details) HTML 51K
62: R49 Income Taxes - Valuation allowance for deferred HTML 25K
tax assets (Details)
63: R50 Commitments and Contingencies - Collaborative HTML 29K
Arrangements and Non-collaborative Arrangement
(Details)
64: R51 Commitments and Contingencies - Defined HTML 29K
Contribution Plan (Details)
65: R52 Leases (Details) HTML 50K
66: R53 Leases - Minimum lease payments (Details) HTML 40K
67: R54 Leases - Lease Portfolio (Details) HTML 45K
68: R55 Net Loss per Share - Weighted Average Shares HTML 39K
(Details)
69: R56 Net Loss per Share - Antidilutive Securities HTML 29K
(Details)
72: XML IDEA XML File -- Filing Summary XML 131K
70: XML XBRL Instance -- ruby-20211231x10k_htm XML 1.60M
71: EXCEL IDEA Workbook of Financial Reports XLSX 91K
10: EX-101.CAL XBRL Calculations -- ruby-20211231_cal XML 169K
11: EX-101.DEF XBRL Definitions -- ruby-20211231_def XML 485K
12: EX-101.LAB XBRL Labels -- ruby-20211231_lab XML 1.21M
13: EX-101.PRE XBRL Presentations -- ruby-20211231_pre XML 855K
9: EX-101.SCH XBRL Schema -- ruby-20211231 XSD 140K
73: JSON XBRL Instance as JSON Data -- MetaLinks 358± 527K
74: ZIP XBRL Zipped Folder -- 0001558370-22-002057-xbrl Zip 998K
Exhibit 21.1
Subsidiary |
| Jurisdiction of Incorporation |
Rubius Therapeutics Securities Corporation | Massachusetts |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/27/23 Rubius Therapeutics, Inc. 10-K 12/31/22 77:7.2M 6/08/22 Rubius Therapeutics, Inc. S-3 6:1M Toppan Merrill/FA |